MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) - Diamond Equity lifted their FY2026 earnings per share (EPS) estimates for shares of MAIA Biotechnology in a report issued on Thursday, November 12th. Diamond Equity analyst H. Diamond now expects that the company will post earnings per share of ($0.48) for the year, up from their previous estimate of ($0.54). The consensus estimate for MAIA Biotechnology's current full-year earnings is ($0.54) per share. Diamond Equity also issued estimates for MAIA Biotechnology's Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.44) EPS.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01.
MAIA Biotechnology Price Performance
MAIA Biotechnology stock opened at $1.01 on Tuesday. MAIA Biotechnology has a one year low of $0.87 and a one year high of $3.19. The business's fifty day moving average is $1.18 and its 200 day moving average is $1.40. The stock has a market capitalization of $62.37 million, a PE ratio of -2.15 and a beta of 0.28.
Insider Transactions at MAIA Biotechnology
In related news, Director Ramiro Guerrero bought 78,239 shares of the stock in a transaction on Thursday, August 27th. The shares were acquired at an average price of $1.39 per share, for a total transaction of $108,752.21. Following the purchase, the director owned 689,081 shares of the company's stock, valued at approximately $957,822.59. The trade was a 12.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vlad Vitoc purchased 73,000 shares of the company's stock in a transaction dated Monday, September 14th. The shares were bought at an average cost of $1.37 per share, for a total transaction of $100,010.00. Following the acquisition, the chief executive officer owned 1,049,121 shares in the company, valued at approximately $1,437,295.77. The trade was a 7.48% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 258,078 shares of company stock valued at $352,426. 19.81% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAIA. Centric Wealth Management purchased a new stake in MAIA Biotechnology during the 2nd quarter valued at $1,107,000. Cable Car Capital LP bought a new position in shares of MAIA Biotechnology during the 2nd quarter valued at $741,000. BlackRock Inc. purchased a new position in shares of MAIA Biotechnology in the 2nd quarter worth $580,000. Marshall Wace LLP purchased a new position in shares of MAIA Biotechnology in the 3rd quarter worth $100,000. Finally, Empowered Funds LLC purchased a new position in shares of MAIA Biotechnology in the 3rd quarter worth $88,000. Institutional investors own 5.65% of the company's stock.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Its research centers on therapies that target telomeres, protective structures at the ends of chromosomes that can help cancer cells continue to divide. The company's lead drug candidate, ateganosine (also known as THIO or 6-thio-dG), is designed to disrupt telomeres in cancer cells and promote their death. MAIA has evaluated ateganosine in clinical research, including studies involving patients with advanced non-small cell lung cancer and treatment in combination with the immunotherapy cemiplimab.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MAIA Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.
While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.